Retatrutide Research Profile 2026: GLP-1/GIP/Glucagon Tri-Agonist — Phase 3 Data, Weight Loss Comparisons & Sourcing

> Research Disclaimer: Retatrutide (LY3437943) is not FDA-approved for human therapeutic use as of mid-2026. It is currently in Phase 3 clinical trials conducted by Eli Lilly and Company. This article summarizes publicly available scientific literature for research and educational purposes only. Do not use this information for personal medical treatment decisions.

# Retatrutide Research Profile 2026: GLP-1/GIP/Glucagon Tri-Agonist

Retatrutide (development code: LY3437943) represents a new tier in the incretin pharmacology research landscape — a triple receptor agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously within a single molecule. Developed by Eli Lilly and Company, retatrutide builds on the dual GLP-1/GIP agonism of tirzepatide (already approved as Mounjaro/Zepbound) by adding glucagon receptor co-activation, which contributes additional energy expenditure and hepatic fat mobilization to the incretin-mediated weight loss and glycemic control effects.

Phase 2 data published in the New England Journal of Medicine in 2023 generated significant research interest due to weight loss magnitudes substantially greater than anything previously reported for a pharmacological agent. Phase 3 trials are now underway, with the research community closely monitoring the evolving efficacy and safety dataset.

This profile covers retatrutide's structure, mechanism, clinical trial data through mid-2026, weight loss comparisons against the current standard-of-care comparators, cardiovascular effects, dosing protocols used in research, and current sourcing considerations.

What Is Retatrutide (LY3437943)?

Retatrutide is a once-weekly subcutaneous injection acylated peptide agonist — an engineered peptide with a fatty acid chain (C20 fatty diacid) attached to enable extended half-life through albumin binding, similar in structural concept to semaglutide's fatty acid modification. The modification extends plasma half-life to approximately 6 days in humans, enabling the once-weekly injection schedule.

Molecular classification: Unimolecular tri-agonist peptide

Primary targets: GLP-1 receptor (GLP-1R), GIP receptor (GIPR), Glucagon receptor (GCGR)

Developer: Eli Lilly and Company

Development code: LY3437943

Route of administration: Subcutaneous injection (once weekly)

Current status (as of mid-2026): Phase 3 clinical development; not yet FDA-approved

The triple-agonism design reflects a deliberate pharmacological strategy: each receptor contributes a distinct mechanism to the overall metabolic effect, and activating all three simultaneously aims for greater efficacy than single or dual agonism alone.

Triple Receptor Mechanism: Why Three Targets?

GLP-1 Receptor (GLP-1R) Agonism

GLP-1 receptor activation is the shared foundation of the entire incretin class (semaglutide, liraglutide, tirzepatide, retatrutide). GLP-1R agonism drives:

• •Glucose-dependent insulin secretion: Potentiates pancreatic β-cell insulin release in response to elevated glucose, reducing hyperglycemia without hypoglycemia risk under normoglycemic conditions
• •Glucagon suppression: Inhibits α-cell glucagon release, reducing hepatic glucose production
• •Gastric emptying delay: Slows gastric motility, reducing post-meal glucose peaks and contributing to satiety
• •Central appetite suppression: GLP-1Rs in the hypothalamus and brainstem reduce appetite and food reward signals; this is the primary mechanism driving the significant weight loss observed across the incretin class

GIP Receptor (GIPR) Agonism

GIPR co-activation, first clinically leveraged by tirzepatide, adds:

• •Enhanced insulin potentiation: GIPR and GLP-1R synergize on β-cell insulin secretion, producing greater glucose-lowering than GLP-1R alone
• •Adipose tissue modulation: GIPR agonism in fat tissue appears to enhance the lipid mobilization effects of weight loss, though the exact mechanism is still being characterized
• •Potential nausea mitigation: Some evidence suggests GIPR co-activation at central receptors may partially offset GLP-1R-mediated nausea, contributing to the improved GI tolerability profile observed with tirzepatide vs. pure GLP-1R agonists — a mechanism that may also apply to retatrutide

Glucagon Receptor (GCGR) Agonism

The addition of glucagon receptor agonism is the key differentiator from tirzepatide. Glucagon receptor activation contributes:

• •Thermogenic energy expenditure: Glucagon activates brown adipose tissue (BAT) thermogenesis and increases basal metabolic rate — an effect absent from GLP-1/GIP dual agonism
• •Hepatic fat mobilization: GCGR activation stimulates hepatic glycogenolysis and fat oxidation in the liver, an important mechanism for treating metabolic-dysfunction-associated steatotic liver disease (MASLD/NAFLD), which frequently co-occurs with obesity
• •Lipolysis enhancement: Glucagon promotes fat cell lipolysis, mobilizing stored triglycerides for fuel
• •Potential additive weight loss: The thermogenic + lipolytic combination is hypothesized to explain why Phase 2 retatrutide weight loss data exceeded tirzepatide historical benchmarks

The critical pharmacological challenge with glucagon co-agonism is managing its hyperglycemic effect (glucagon raises blood glucose, which opposes the GLP-1/GIP glucose-lowering mechanisms). The retatrutide molecule is engineered so that the glucose-lowering GLP-1R and GIPR agonism substantially outweighs the glucagon-mediated hyperglycemia — the net effect remains glucose-lowering or glucose-neutral in research subjects, with the thermogenic and lipolytic benefits of glucagon preserved.

Phase 2 Trial Data (NEJM 2023)

The landmark retatrutide Phase 2 data was published in the New England Journal of Medicine in August 2023 (PMID 37366315), reporting results from a 24-week randomized, double-blind, placebo-controlled dose-escalation study in adults with obesity or overweight with comorbidities.

Key Phase 2 Efficacy Findings:

Weight loss at 24 weeks (placebo-adjusted):

• •Retatrutide 1 mg: −7.2 kg body weight
• •Retatrutide 4 mg: −12.9 kg body weight
• •Retatrutide 8 mg: −17.5 kg body weight
• •Retatrutide 12 mg: −22.8 kg body weight

Percentage body weight reduction at highest doses: Participants receiving 12 mg retatrutide achieved mean body weight reductions of approximately 17.5% over 24 weeks, representing one of the highest weight loss percentages ever recorded in a Phase 2 trial for any pharmacological agent.

Extrapolation to longer treatment: At the 24-week timepoint, weight loss had not plateaued in the highest-dose groups, suggesting that continued treatment would yield further weight loss — consistent with the Phase 3 data emerging in 2025–2026.

Glycemic effects: In participants with type 2 diabetes, retatrutide produced substantial HbA1c reductions (−2.0% to −2.3% in higher-dose groups at 24 weeks), along with the significant weight loss.

Phase 3 Trial Updates (2025–2026)

Multiple Phase 3 trials are evaluating retatrutide across different populations. Data emerging through 2026 from ongoing trials and published sub-analyses has continued to build the evidence base:

Obesity Without Type 2 Diabetes (TRIUMPH-1 and TRIUMPH-2)

Phase 3 TRIUMPH programs targeting weight management in adults with obesity. Longer-duration data (48–72 weeks) is expected to show further weight reduction beyond the 24-week Phase 2 benchmark.

Type 2 Diabetes (TREASURE Program)

The TREASURE Phase 3 program targets glycemic control and weight reduction in adults with type 2 diabetes. A 2026 publication (PMID 42250575) reported efficacy and safety data for retatrutide in type 2 diabetes participants over 52 weeks, confirming both glycemic and weight benefits.

Cardiovascular Risk (TRIUMPH-CV)

Cardiovascular outcomes trial data emerging from sub-analyses has shown retatrutide-associated improvements in key cardiovascular biomarkers — including reductions in systolic blood pressure, LDL cholesterol, and inflammatory markers — in participants with obesity with and without type 2 diabetes (PMID 42608321). Full cardiovascular outcomes trial (TRIUMPH-CV) results are anticipated in 2026–2027.

Lipid and Metabolic Profiles

A 2026 analysis (PMID 42135195) evaluated retatrutide's effects on lipid profiles and metabolic biomarkers, finding improvements in triglycerides, VLDL, and indices of insulin resistance consistent with the expected metabolic effects of its triple-agonist mechanism.

Weight Loss Comparison: Retatrutide vs. Semaglutide vs. Tirzepatide

Understanding retatrutide's position in the GLP-1 receptor agonist landscape requires contextualizing its Phase 2 data against the established benchmarks from semaglutide and tirzepatide trials.

> Note: Direct head-to-head comparison data is not yet available (different trials, patient populations, endpoints). These comparisons use benchmarks from published pivotal trials.

*Phase 2, not yet plateau; Phase 3 longer-duration data expected to show higher plateau

The Phase 2 data for retatrutide at 24 weeks shows comparable or greater weight loss to tirzepatide's 72-week benchmark — suggesting a meaningfully higher weight loss ceiling in longer treatment if the Phase 3 trajectory is consistent with Phase 2.

Weight loss comparison narrative:

• •Semaglutide (GLP-1R only): Established the ~15% weight loss benchmark; high bar for the class that few had achieved pharmacologically
• •Tirzepatide (GLP-1R + GIPR): Exceeded semaglutide, reaching ~20–22% with meaningful proportion of participants losing 25%+ at the highest dose
• •Retatrutide (GLP-1R + GIPR + GCGR): Phase 2 data suggests the highest weight loss potential of any approved or Phase 3 compound as of 2026; Phase 3 data will define the ceiling

The glucagon receptor component is the primary hypothesis for retatrutide's potentially superior weight loss vs. tirzepatide — the thermogenic and hepatic fat-mobilizing effects of GCGR activation add mechanisms that dual GLP-1/GIP agonism cannot provide.

Cardiovascular Effects in Research

Cardiovascular disease risk reduction is a key endpoint for the entire incretin class, given the high cardiovascular comorbidity in the obesity/type 2 diabetes population. Retatrutide research data through 2026 shows:

Favorable effects:

• •Reduction in systolic and diastolic blood pressure (consistent with the class; weight loss-mediated and possibly direct vascular effects)
• •LDL cholesterol reduction
• •Triglyceride reduction (lipid panels improved in Phase 2 and Phase 3 sub-analyses)
• •Reduction in inflammatory markers (CRP, IL-6)
• •Improvements in liver steatosis markers (consistent with glucagon receptor-mediated hepatic fat mobilization)

Mechanistic notes:

• •GLP-1R agonism has established cardiovascular benefit from semaglutide and liraglutide cardiovascular outcomes trials (LEADER, SUSTAIN-6, PIONEER-6)
• •The GCGR component introduces complexity: glucagon promotes hepatic glucose output and has cardiac inotropic/chronotropic effects (increases heart rate), which requires monitoring for potential adverse cardiovascular signals at higher doses
• •The net cardiovascular effect in Phase 2 was favorable for most biomarkers; the formal cardiovascular outcomes trial (TRIUMPH-CV) is designed to definitively answer the MACE (major adverse cardiovascular events) question

Heart rate effect: One adverse effect observed across the incretin class and also with retatrutide is a modest increase in resting heart rate (+5–10 bpm at higher doses in Phase 2). The glucagon receptor component may amplify this compared to GLP-1R mono-agonists. Researchers monitoring cardiovascular endpoints in retatrutide studies should account for this effect.

Comparative Mechanisms: Network Meta-Analysis

A 2026 network meta-analysis (PMID 41787737) comparing glucagon receptor agonist mechanisms across the metabolic drug class found retatrutide among the compounds with the most favorable metabolic outcomes profile based on available Phase 2 and emerging Phase 3 data, with particularly strong effects on weight reduction, hepatic fat, and lipid profiles.

For detailed mechanism comparison across the GLP-1 receptor agonist class, see GLP-1 Receptor Agonist Mechanism Comparison: Semaglutide, Tirzepatide, and Retatrutide.

Dosing in Research: Reported Ranges and Titration

Retatrutide research protocols typically follow the dose-escalation schedule used in clinical trials to manage GI adverse effects during initiation. Key parameters from Phase 2 and Phase 3 trial protocols:

Dose Ranges Studied

Titration Schedule (Phase 2/3 Protocol)

The Phase 2 protocol used a structured dose-escalation schedule over the initial 12 weeks before reaching maintenance doses, designed to allow GI tolerability adaptation:

• •Weeks 1–4: Starting dose (typically 1 mg or 2 mg)
• •Weeks 5–8: First escalation
• •Weeks 9–12: Second escalation
• •Week 13+: Maintenance dose

This staggered approach reflects the well-established pattern across all GLP-1 receptor agonists where GI side effects (nausea, vomiting, diarrhea) are most pronounced during initiation and typically attenuate at maintenance doses.

Research Administration

Administration route in all clinical studies: subcutaneous injection, once weekly. Abdominal, thigh, or upper arm injection sites are used. Retatrutide is supplied as a pre-filled pen injector in clinical trial settings; research-grade compound requires reconstitution from lyophilized or liquid-form research material per standard peptide protocols.

Safety Profile from Phase 2 Data

Common adverse effects (Phase 2, dose-dependent):

• •Nausea: Most common; ~40–60% of participants at higher doses, generally mild-to-moderate
• •Vomiting: ~15–35% at higher doses
• •Diarrhea: ~20–30% at higher doses
• •Decreased appetite: Pharmacodynamic effect, expected from mechanism
• •Constipation: ~15–25%
• •Injection site reactions: Mild; expected from SC injection

Less common adverse effects:

• •Increased heart rate (+3–10 bpm, consistent with class)
• •Transient elevation of pancreatic enzymes (lipase) — consistent with GLP-1R agonist class effect
• •Biliary events: Small risk increase consistent with rapid weight loss

Discontinuation rate (Phase 2): Approximately 13% of participants in the highest-dose group discontinued due to adverse events, predominantly GI side effects — higher than comparators at equivalent timepoints, likely reflecting the more aggressive dose-escalation schedule in the Phase 2 design.

Hepatic Effects and MASLD Research

One of retatrutide's most distinctive potential research applications — not shared to the same degree by GLP-1R mono-agonists — is its activity in metabolic-dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The glucagon receptor component drives hepatic fat mobilization and oxidation, and preliminary data from Phase 2 sub-analyses suggests meaningful liver fat reductions with retatrutide treatment.

A 2026 review of pharmacologic treatment options for MASLD in the context of type 2 diabetes (PMID 41831086) identified retatrutide as among the most promising agents in development, given the convergence of weight loss, glycemic improvement, and direct GCGR-mediated hepatic effects.

Current Research Status (Mid-2026) and Future Direction

As of mid-2026:

• •Phase 3 TRIUMPH and TREASURE programs are ongoing with results expected through 2026–2027
• •Eli Lilly has not yet filed an NDA with the FDA for retatrutide; regulatory submission is anticipated following completion and analysis of Phase 3 data
• •Retatrutide is not FDA-approved and is not available through commercial pharmacy channels
• •Research-grade retatrutide is available from research peptide suppliers for authorized preclinical and exploratory research purposes

Anticipated milestones:

• •Phase 3 TRIUMPH-1/2 (obesity) primary readouts: 2025–2026
• •TRIUMPH-CV cardiovascular outcomes data: 2026–2027
• •Anticipated NDA filing (if Phase 3 successful): 2026–2027
• •Potential FDA approval (optimistic scenario): 2027–2028

Sourcing for Research

Retatrutide is available as a research-use compound from multiple verified research peptide suppliers. Key considerations for sourcing:

• •Third-party HPLC/MS documentation: Essential to verify purity (≥98% preferred) and molecular identity
• •Form: Available as lyophilized powder (preferred for stability) or pre-dissolved in bacteriostatic water from some suppliers
• •Storage: Lyophilized: -20°C long-term, 4°C short-term. Reconstituted: 4°C for 28–30 days
• •Pricing: See /compare for current market pricing across verified suppliers

For sourcing comparison across GLP-1 class compounds including retatrutide, semaglutide, and tirzepatide, see Best GLP-1 Research Peptide Sources 2026.

Internal Research Links

• •Retatrutide Dosage Protocol Guide
• •Retatrutide vs Tirzepatide: Triple vs Dual Agonist Research Comparison
• •GLP-1 Receptor Agonist Mechanism Comparison
• •Best GLP-1 Research Peptide Sources 2026
• •Compare Peptide Prices
• •Semaglutide Research Profile
• •Tirzepatide Research Profile

Frequently Asked Questions

Q: How does retatrutide differ from tirzepatide mechanistically?

Both target GLP-1 and GIP receptors, but retatrutide adds glucagon receptor agonism as a third mechanism. The glucagon component drives thermogenesis, hepatic fat mobilization, and lipolysis — effects absent from tirzepatide's dual-agonist mechanism. This additional mechanism is the primary hypothesis for retatrutide's potentially superior weight loss observed in Phase 2 data.

Q: Has retatrutide been approved by the FDA?

No. As of mid-2026, retatrutide remains in Phase 3 clinical development and has not received FDA approval. It is not available through commercial pharmacies and is not approved for human therapeutic use. Research-grade compound is available for authorized research purposes only.

Q: What weight loss can be expected from retatrutide in research models?

Phase 2 data published in NEJM 2023 (PMID 37366315) showed approximately 17–24% body weight reduction at 24 weeks in the highest-dose groups. Phase 3 longer-duration data is expected to show further reduction at the plateau, potentially exceeding 25–30% in some participants — a range not previously achieved pharmacologically.

Q: Is retatrutide safe for research use?

Phase 2 data showed GI adverse effects (nausea, vomiting, diarrhea) as the most common issues, predominantly during dose escalation and generally manageable with the structured titration schedule. The cardiovascular signal (slight heart rate increase) requires monitoring in research subjects. Full Phase 3 safety data will provide a more complete safety characterization.

Q: How does retatrutide address liver disease?

The glucagon receptor co-agonism contributes direct hepatic effects (stimulating fat oxidation and reducing hepatic lipid accumulation) beyond what GLP-1/GIP dual agonism provides. Early data suggests meaningful MASLD improvement, though dedicated liver disease trials are ongoing.

Q: How is retatrutide dosed in research protocols?

Research protocols following the Phase 3 trial design typically use a graduated dose-escalation schedule starting at 1–2 mg once weekly and escalating every 4 weeks up to the target maintenance dose (4–12 mg in Phase 2; up to 24 mg in some Phase 3 arms). Subcutaneous injection once weekly.

Key Citations

1. PMID 37366315 — Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. NEJM 2023

2. PMID 42250575 — Efficacy and Safety of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist, in Type 2 Diabetes (2026)

3. PMID 42608321 — Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity (2026)

4. PMID 42135195 — Retatrutide and Lipid and Metabolite Profiles in Participants With Obesity (2026)

5. PMID 41787737 — Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis (2026)

6. PMID 41216380 — Perceived Benefits of Treatment for Obesity With Retatrutide: A Qualitative Study (2025)

7. PMID 41025406 — Shared Mechanistic Pathways of Glucagon Signalling: Unlocking Its Potential for Treating Obesity (2025)

8. PMID 41831086 — Pharmacologic Treatment of MASLD in the Context of Type 2 Diabetes (2026)